atai Life Sciences to Participate in Upcoming June Investor Conferences

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

BREAKING: State of Kentucky Sets aside $42 Million for Psychedelic Research,...

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office...

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation...

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks...

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

PT412 – Psychedelics and Virtual Reality: Where Novel Experience, Technology, and...

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part...

FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT...

Load more